Pharma wants more balanced payment system in Europe; China's pharma industry records steady 2013 growth;

@FiercePharma: AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says. More | Follow @FiercePharma

@TracyStaton: With new study, Pfizer closes in on $1B-plus sales boost for #Prevnar vaccine. More | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. Article | Follow @EricPFierce

@CarlyHFierce: Vivus beats the street on licensing payments, but investors aren't fooled. Story | Follow @CarlyHFierce

> The pharma industry has called on the European Medicines Agency (EMA) to reexamine how it handles pharmacovigilance payments, angling for a more "balanced and transparent" system. More

> Pfizer ($PFE) is resuming shipping of thyroid-disorder drug Levoxyl, which was in short supply after a manufacturing quality problem spurred a recall. Report (sub. req.)

> China's pharmaceutical industry saw steady growth in 2013, with revenues increasing 17.9% to about $355.4 billion. Story

> The FDA has approved Iroko's Tivorbex, a non-steroidal anti-inflammatory. Release

Medical Device News

@FierceMedDev: Boston Scientific is trying to nip at Medtronic's heels, as far as neuromodulation goes. Has it been successful? Report | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical may not be #1 in neuromodulation, but it is pushing hard to get there. Report | Follow @MarkHFierce

@MichaelGFierce: An FDA panel wants to change iontophoresis drug delivery regulation. More (reg. req) | Follow @MichaelGFierce

@EmilyWFierce: Practice Fusion is teaming up with medical device companies to provide "real-time" accounts of patient health. Article  | Follow @EmilyWFierce

> Volcano moves the bar a notch higher for 2014 as restructuring continues. Story

> MIT, Apple and others help shape Quanttus' wearable clinical monitoring tech. More

> India moves closer to approving key medical device legislation. News

Biotech News

@FierceBiotech: Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal. Story | Follow @FierceBiotech

@JohnCFierce: Have to wonder about these bullish peak sales forecasts on dulaglutide. Are patients ready to switch based on easier dosing? | Follow @JohnCFierce

@DamianFierce: InterMune trading up 150% premarket. Here's why. | Follow @DamianFierce

@EmilyMFierce: Global tuberculosis R&D takes hit with AstraZeneca site closure. News | Follow @EmilyMFierce

> Antibiotics player Achaogen sets terms on $65M IPO. More

> Merck scuttles a $700M-plus Ariad deal and hands back a once-vaunted cancer drug. Article

Pharma Manufacturing News

> The FDA catches another Indian drugmaker falsifying data. News

> Ranbaxy halts production at 2 plants to tackle its regulatory mess. Story

> The FDA has expanded its equivalency testing of generics. Article

> GSK vows to maintain soccer fields in new U.K. plant. Story

> Hamburg says FDA's focus on India reflects its place in the global supply chain. Story

> Pfizer and MIT are looking for more efficient biologics manufacturing. Brief

Biotech Research News

> Gene therapy regenerates damaged tissue in pigs after heart attack. Story

> Reprogrammed skin cells could provide a way to regenerate liver tissue. Article

> Global tuberculosis R&D takes hit with AstraZeneca site closure. News

> HPV-like vaccine guards against skin tumors in mice. Article

> DOD selects Bavarian Nordic to develop vaccine against biological threats. News

> Berg, Parkinson's Institute partner to find biomarkers. Brief

And Finally... The bosses beind GlaxoSmithKline's ($GSK) £350 million ($584 million) development in Ulverston, U.K., say they're dedicated to replacing the site's existing sports facilities; plans include a new sports hall, new soccer pitches and a bowling green. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.